Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

GenSight Biologics SA (GSGTF) Stock Price & Analysis

0 Followers

GSGTF Stock Chart & Stats

$0.08$0.00(0.00%)
At close: 4:00 PM EST
$0.08$0.09$0.1Aug 14Aug 31Oct 1
Day’s Range
$0.08 - $0.08
52-Week Range
$0.08 - $0.19
Previous Close
$0.08
Volume
N/A
Average Volume (3M)
3
Market Cap
$20.46M
Enterprise Value
$29.15M
Total Cash (Recent Filing)
$1.67M
Total Debt (Recent Filing)
$12.84M
Price to Earnings (P/E)
―
Beta
-0.03
Next Earnings
Mar 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Lower Debt

Debt reduction from prior years is a constructive balance-sheet development that can lower repayment pressure and improve financial flexibility. Although solvency remains weak, a smaller debt burden may help management preserve resources for advancing the clinical pipeline and managing near-term funding needs.

Improved Cash Burn

The reduction in operating cash burn indicates some progress in controlling cash consumption, even though the company remains cash-flow negative. If sustained, this improvement could extend the period available to develop clinical programs and reduce the pace of future financing requirements.

Specialized Therapeutic Pipeline

GenSight’s focus on gene therapy and optogenetics addresses severe retinal neurodegenerative and inherited disorders, with LUMEVOQ and GS030 forming a specialized ophthalmology pipeline. This differentiated scientific focus could support long-term value creation if clinical development and regulatory progress succeed.

Bears Say

Revenue Collapse

The near-total revenue decline highlights the company’s limited commercial scale and weak visibility into recurring operating income. Without a meaningful recovery in revenue, GenSight will have less internal funding for research, clinical development, and corporate expenses, increasing dependence on external capital.

Negative Shareholders’ Equity

Persistently negative shareholders’ equity is a structural solvency concern and indicates that accumulated financial deficits have eroded the capital base. This weakens balance-sheet resilience, limits financial flexibility, and makes the company more vulnerable if additional funding becomes difficult to secure.

Persistent Losses And Cash Burn

Recurring net losses and negative operating cash flow show that the business has not yet reached self-sustaining operations. Continued cash consumption can constrain investment in the pipeline, require repeated financing, and increase execution risk until products generate meaningful commercial revenue.

GenSight Biologics SA News

GSGTF FAQ

What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest stock price was $0.08 and its highest was $0.19 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is $20.46M.
When is GenSight Biologics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Sep 29, 2026. The company reported -$0.057 earnings per share for the quarter.
Is GenSight Biologics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 246,217,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -$0.057 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in GSGTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology